Status:
ENROLLING_BY_INVITATION
GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES
Lead Sponsor:
Karolinska University Hospital
Collaborating Sponsors:
Universitätsklinikum Hamburg-Eppendorf
Aarhus University Hospital
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The overall objective of this study is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical ...
Detailed Description
The study will prospectively enroll patients who undergo potentially curative surgery for PDAC. The intervention is repeated blood sampling at pre-defined time points. Patient identification Patients...
Eligibility Criteria
Inclusion
- Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
- Age 18 years or older.
- Patient able to understand and sign written informed consent in Swedish.
- Scheduled for curative intent surgical resection.
Exclusion
- Hereditary pancreatic cancer.
- Verified distant metastases.
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
- Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.
Key Trial Info
Start Date :
May 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06102889
Start Date
May 2 2024
End Date
December 31 2026
Last Update
April 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastrocentrum, KarolinskaUniversity Hospital
Stockholm, Sweden, 14186